CN103006661A - Preparation containing lurasidone hydrochloride and preparation method thereof - Google Patents
Preparation containing lurasidone hydrochloride and preparation method thereof Download PDFInfo
- Publication number
- CN103006661A CN103006661A CN2012105198541A CN201210519854A CN103006661A CN 103006661 A CN103006661 A CN 103006661A CN 2012105198541 A CN2012105198541 A CN 2012105198541A CN 201210519854 A CN201210519854 A CN 201210519854A CN 103006661 A CN103006661 A CN 103006661A
- Authority
- CN
- China
- Prior art keywords
- preparation
- lurasidone hcl
- oral formulations
- formulation
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to an oral preparation and a preparation method thereof. The preparation contains lurasidone hydrochloride, a micronized particle of a dispersion supporter, microcrystalline cellulose and a water-soluble polymer adhesive. More specifically, the invention relates to the oral preparation and especially to a tablet. The preparation has a fast dissolution characteristic, and dissolution characteristics of an active component are identical; even though the content of the active component in the preparation changes in a certain range, the dissolution characteristics of the active component are still identical.
Description
Technical field
The present invention relates to a kind of oral formulations and preparation method, said preparation contains micronized particle, microcrystalline Cellulose and the water-soluble copolymer adhesive of Lurasidone HCl and dispersible carrier, more specifically, the present invention relates to oral formulations, tablet particularly, said preparation has faster dissolution characteristic, and has identical active component dissolution characteristic, even also be like this when the content of its active component changes within the specific limits.
Background technology
Lurasidone HCl ((3aR, 4S, 7R, 7aS)-2-[(1R, 2R)-and 2-[4-(1,2-benzisothiazole-3-yl) piperazine-1-ylmethyl] cyclohexyl methyl] six hydrogen-1H-4,7-methyl iso-indoles-1, the 3-dione hydrochloride), namely have the chemical compound shown in the following general formula (1):
Lurasidone HCl is known to have antipsychotic effect, and it can be used as the medicine for schizophrenia etc.
But patent documentation 1 discloses the such chemical compound oral administration administration of Lurasidone HCl, but not open a kind of like this oral formulations in the document, wherein active component content increases in the said preparation, and its dissolution characteristic is similar to the active component dissolution characteristic that has in the multiple medicines of lower content in every.
In order to ensure the purpose that realizes after administration has the pharmaceutical preparation of active component of different content, having bioequivalence, thereby make and have each other identical dosage, people have published a this guide, i.e. " the oral dosage form bioequivalence Guide to research with different content " (Notification No.64 of the Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, promulgated on February14,2000), wherein the pharmaceutical preparation that requires to have different content of this guide should have identical dissolution characteristic in each test solution, described test solution such as PH are 1.2,3.0 (it is equivalent to respectively gastric juice to the buffer to 5. and 6.8, the pH value that intestinal and oral cavity go out), water and saline solution.
Patent documentation 2 discloses and has contained Lurasidone HCl as the oral formulations of active component, and said preparation has instant capacity.Particularly the document discloses the oral formulations that a kind of active component content increases, the dissolution characteristic of said preparation to every in to have a dissolution characteristic of multiple medicines of lower content similar, and can from said preparation, discharge the active component that is slightly soluble in water with desired concn.
Patent documentation 2 further discloses a kind of oral formulations, a kind of tablet particularly, and the active component of this tablet can be instant, even also can be instant when active component changes in the scope of 5mg to 40mg in preparation.4 kinds of preparation methoies are disclosed in the document:
1) the first disintegrating agent and water soluble excipient are mixed, add subsequently the slightly water-soluble effective ingredient and mix, use the water soluble polymer bonding agent to be made into the solid formed body, it is mixed with the second disintegrating agent and preparation;
2) the first disintegrating agent, water soluble excipient and slightly water-soluble effective ingredient are mixed, use the water soluble polymer bonding agent to be made into the solid formed body, it is mixed with the second disintegrating agent and preparation;
3) the first disintegrating agent is mixed with sugar alcohol, add subsequently the slightly water-soluble effective ingredient and mix, use the water soluble polymer bonding agent, be made into the solid formed body and preparation;
4) the first disintegrating agent, sugar alcohol are mixed and the mixing of slightly water-soluble effective ingredient, use the water soluble polymer bonding agent, be made into the solid formed body and preparation.
The document discloses when active component changes in the scope of 5mg to 40mg has identical dissolution characteristic, when active component content increases, does not then have this characteristic.
Patent documentation 3 discloses and has contained Lurasidone HCl as the oral formulations of active component, and said preparation has instant capacity.Provide scope to have the oral formulations of identical dissolution characteristic to 40mg to 120mg Lurasidone HCl/sheet in the description.And disclosed oral formulations in the patent documentation 2 is provided, and when the content of every middle active component doubled, when being the 80mg tablet, this tablet did not namely have identical dissolution characteristic.Prepare according to patent documentation 3, every middle active component increases to the tablet of 160mg, and this tablet no longer has identical dissolution characteristic, as shown in Figure 1.Be slightly soluble in like this active component of water for Lurasidone HCl, be difficult to provide the oral formulations of identical dissolution characteristic.
Patent documentation 3 has been protected the oral formulations that contains Lurasidone HCl, pre-gelatinized starch, water soluble excipient and water-soluble copolymer adhesive; and oral formulations provided by the invention contains the micronized particle of Lurasidone HCl and dispersible carrier; and provide the preparation method different from patent documentation 2; reached and had faster dissolution characteristic; and have the characteristic of identical active component stripping, even also be like this when the content of its active component is higher.
Patent documentation 1:JP2800953; Patent documentation 2:WO2002/024166; Patent documentation 3:CN101184489B.
Summary of the invention
The purpose of this invention is to provide a kind of oral formulations with Lurasidone HCl of high-load, said preparation has faster dissolution characteristic, and have identical active component dissolution characteristic, even also be like this when the content of its active component changes within the specific limits.Particularly the invention provides the oral formulations that a kind of active component content increases, the dissolution characteristic of the multiple medicines that the dissolution characteristic of said preparation and every middle active component content are lower is similar, and can discharge active component with desired concn from said preparation.
Another object of the present invention provides a kind of method for preparing this oral formulations.
For achieving the above object, the present invention takes following technical scheme:
A kind of oral formulations contains the micronized particle of Lurasidone HCl and dispersible carrier, and the mean diameter of the micronized particle of wherein said Lurasidone HCl and dispersible carrier is 0.1-12 μ m.
In oral formulations of the present invention, described dispersible carrier is Polyethylene Glycol, polyvinylpyrrolidone, poloxamer, polyethylene oxide, mannitol, lactose or sucrose, and the dispersible carrier total amount be weight of formulation 10-75% (wt/wt), being preferably 20-55% (wt/wt), more preferably is 24-50% (wt/wt).
In oral formulations of the present invention, also contain microcrystalline Cellulose and water-soluble copolymer adhesive, the 10-45% (wt/wt) that described microcrystalline Cellulose total amount is weight of formulation is preferably 15-40% (wt/wt); The water-soluble copolymer adhesive total amount is the 0.5-10% (wt/wt) of weight of formulation, is preferably 1-3% (wt/wt).
In oral formulations of the present invention, the 10-50% (wt/wt) that described Lurasidone HCl content is weight of formulation is preferably 20-45% (wt/wt), more preferably is 22-25% (wt/wt).
In oral formulations of the present invention, the Lurasidone HCl content in every is 20-160mg, is preferably 120-160mg.
A kind of preparation method of oral formulations; comprise the Lurasidone HCl in the preparation with after dispersible carrier mixes; adopt the method for grinding and pulverizing to disperse to form micronized particle; adopt the water-soluble copolymer adhesive granulation after adding microcrystalline Cellulose, the mean diameter of the micronized particle of wherein said Lurasidone HCl and dispersible carrier is 0.1-12 μ m.
Oral formulations preparation method among the present invention is specially:
(1) aqueous solution of preparation water-soluble copolymer adhesive: water-soluble copolymer adhesive is soluble in water.The total amount of water-soluble copolymer adhesive is the 1-20% (wt/wt) of pure water weight, is preferably 2-8% (wt/wt);
(2) micronized particle of preparation Lurasidone HCl and mannitol: Lurasidone HCl and mannitol are mixed, grind and be crushed to the micronized particle that mean diameter is 0.1-12 μ m;
(3) granulate: add micronized particle, microcrystalline Cellulose and the part disintegrating agent of Lurasidone HCl and mannitol in the shear granulation machine, pour the water-soluble copolymer adhesive that disposes in the step (1) into and carry out granulation.Dried particles: with above-mentioned granule under atmospheric pressure dry, dry standard be that loss on drying is in the 3wt%, be preferably 1-2% (wt/wt);
(4) sneak into lubricant and residue disintegrating agent: in (3) gained granule, sneak into lubricant and residue disintegrating agent;
(5) tabletting: the said mixture compacting is obtained tablet;
(6) film coating: optional material carries out film coating, and coating material is hypromellose, polyvinyl alcohol or hyprolose for example, and plasticizer is Polyethylene Glycol, propylene glycol or glycerol for example.
In the preparation method of oral formulations of the present invention, described dispersible carrier is Polyethylene Glycol, polyvinylpyrrolidone, poloxamer, polyethylene oxide, mannitol, lactose or sucrose, and the dispersible carrier total amount be weight of formulation 10-75% (wt/wt), being preferably 20-55% (wt/wt), more preferably is 24-50% (wt/wt).。
In the preparation method of oral formulations of the present invention, the 10-45% (wt/wt) that described microcrystalline Cellulose total amount is weight of formulation is preferably 15-40% (wt/wt); The water-soluble copolymer adhesive total amount is the 0.5-10% (wt/wt) of weight of formulation, is preferably 1-3% (wt/wt).
In the preparation method of oral formulations of the present invention, the 10-50% (wt/wt) that described Lurasidone HCl content is weight of formulation is preferably 20-45% (wt/wt), more preferably is 22-25% (wt/wt).
In the preparation method of oral formulations of the present invention, the Lurasidone HCl content in every is 20-160mg, is preferably 120-160mg.
Below will explain in detail suitable example and the explanation of a plurality of definition mentioned in the description of this context.
Term " dispersible carrier " comprises for example Polyethylene Glycol, polyvinylpyrrolidone, poloxamer, polyethylene oxide, mannitol, sucrose or lactose.Preferably include mannitol, sucrose or lactose.More preferably be mannitol.Equally, dispersible carrier can use separately, also can two or more unite use.
Term " microcrystalline Cellulose " refers to the microcrystalline Cellulose of various shapes of particle, comprises for example PH101, PH102, PH200, PH301, PH302, KG802 or KG1000.Preferably include PH101, PH301 or KG802.Most preferably comprise KG802.Described microcrystalline Cellulose can use separately also can two or more unite use.
Term " water-soluble copolymer adhesive " comprises for example hyprolose, hypromellose or polyvinylpyrrolidone.Preferably include hyprolose or hypromellose.Described water-soluble copolymer adhesive can use separately also can two or more unite use.
Term " micronization " refers to solid drugs is ground into the process of micropowder.Micropowder is the aggregation of fine particle, and the particle diameter that forms segmentation can be little of 0.1 μ m.
Term " micronized particle " refers to via the granule that forms behind the said process.
Description of drawings
Fig. 1 has shown the contrast of the dissolution characteristic of the preparation with different Lurasidone HCl content.Preparation according to patent documentation 3 disclosed technology preparations is carried out dissolution characteristic measure, the content of its every middle Lurasidone HCl is 40mg (2), 80mg (1), 80mg (2) and 160mg (1).
Fig. 2 has shown the dissolution characteristic contrast that different Lurasidone HCls contain volume preparation that has provided by the invention, and the content of its every middle Lurasidone HCl is followed successively by 120mg, 120mg, 120mg, 160mg, 160mg and 160mg.
Beneficial effect of the present invention
1. the micronized particle of a kind of Lurasidone HCl and dispersible carrier is provided, has made the oral formulations that makes, when containing more the high-load Lurasidone HCl, also had the preparation of identical dissolution characteristic.
2. a kind of new preparation method is provided, easy and simple to handle, improve the active component dissolution characteristic.
3. a kind of preparation of suitable long term storage is provided.
Specific implementation method
The present invention will be described below by infinite embodiment, should be understood to, and preferred embodiment described herein only is used for description and interpretation the present invention, is not intended to limit the present invention.
Embodiment
Prescription:
Preparation method:
1) it is for subsequent use each supplementary material to be crossed 40 mesh sieves.
2) take by weighing recipe quantity Lurasidone HCl and mannitol, mix homogeneously.Pulverizing obtains microsome granule A.
3) preparation 5% hypromellose solution obtains solution B.
4) in microsome granule A, add microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose mix homogeneously, obtain mixture C.
5) add solution B in mixture C and make soft material, 14 orders are granulated, and 55 ℃ are dried to weightless 1-3% (wt/wt), and 14 order granulate obtain granule D.
6) in granule D, add silicon dioxide, magnesium stearate, mix homogeneously gets intermediate.
7) intermediate detects.
8) according to intermediate testing result tabletting.
9) preparation 12% Opadry, coating.
The dissolution characteristic test:
The dissolution characteristic test is carried out dissolution test by Chinese Pharmacopoeia the second method.Testing liquid is dilution McIlvaine buffer, pH3.8,50rpm, experimental liquid: 900ml.
Reached a conclusion by the result, the tablet for preparing Lurasidone HCl 120mg and 160mg according to method disclosed by the invention shows instant capacity, and having identical active component dissolution characteristic, also is so even active component content wherein changes, as shown in Figure 2.
The product practicality:
The present invention can provide a kind of preparation for the good dissolution characteristic of having of oral administration, said preparation contains Lurasidone HCl as active component, it has identical active component dissolution characteristic, also is like this even active component content wherein changes.
Need to prove at last: the above only is part preferred embodiment of the present invention, be not limited to the present invention, although with reference to previous embodiment the present invention is had been described in detail, for those skilled in the art, it still can be made amendment to the technical scheme that previous embodiment is put down in writing, and perhaps wherein part technical characterictic is equal to replacement.Within the spirit and principles in the present invention all, any modification of making, be equal to replacement, improvement etc., all should be included within protection scope of the present invention.
Claims (10)
1. oral formulations, it is characterized in that: said preparation contains the micronized particle of Lurasidone HCl and dispersible carrier, and the mean diameter of the micronized particle of wherein said Lurasidone HCl and dispersible carrier is 0.1-12 μ m.
2. oral formulations according to claim 1, it is characterized in that: described dispersible carrier is Polyethylene Glycol, polyvinylpyrrolidone, poloxamer, polyethylene oxide, mannitol, lactose or sucrose, and the dispersible carrier total amount is the 10-75% (wt/wt) of weight of formulation, being preferably 20-55% (wt/wt), more preferably is 24-50% (wt/wt).
3. oral formulations according to claim 1, it is characterized in that: said preparation also contains microcrystalline Cellulose and water-soluble copolymer adhesive, the 10-45% (wt/wt) that described microcrystalline Cellulose total amount is weight of formulation, be preferably 15-40% (wt/wt), the water-soluble copolymer adhesive total amount is the 0.5-10% (wt/wt) of weight of formulation, is preferably 1-3% (wt/wt).
4. oral formulations according to claim 1 is characterized in that: the 10-50% (wt/wt) that described Lurasidone HCl content is weight of formulation, be preferably 20-45% (wt/wt), and more preferably be 22-25% (wt/wt).
5. oral formulations according to claim 1, it is characterized in that: the Lurasidone HCl content in every is 20-160mg, is preferably 120-160mg.
6. the preparation method of an oral formulations; it is characterized in that: the method comprises the Lurasidone HCl in the preparation with after dispersible carrier mixes; adopt the method for grinding and pulverizing to disperse to form micronized particle; adopt the water-soluble copolymer adhesive granulation after adding microcrystalline Cellulose, the mean diameter of the micronized particle of wherein said Lurasidone HCl and dispersible carrier is 0.1-12 μ m.
7. preparation method according to claim 6, it is characterized in that: described dispersible carrier is Polyethylene Glycol, polyvinylpyrrolidone, poloxamer, polyethylene oxide, mannitol, lactose or sucrose, and the dispersible carrier total amount is the 10-75% (wt/wt) of weight of formulation, being preferably 20-55% (wt/wt), more preferably is 24-50% (wt/wt).
8. preparation method according to claim 6, it is characterized in that: the 10-45% (wt/wt) that described microcrystalline Cellulose total amount is weight of formulation, be preferably 15-40% (wt/wt), the water-soluble copolymer adhesive total amount is the 0.5-10% (wt/wt) of weight of formulation, is preferably 1-3% (wt/wt).
9. preparation method according to claim 6 is characterized in that: the 10-50% (wt/wt) that described Lurasidone HCl content is weight of formulation, be preferably 20-45% (wt/wt), and more preferably be 22-25% (wt/wt).
10. preparation method according to claim 6, it is characterized in that: the Lurasidone HCl content in every is 20-160mg, is preferably 120-160mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210519854.1A CN103006661B (en) | 2012-12-06 | 2012-12-06 | Preparation containing lurasidone hydrochloride and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210519854.1A CN103006661B (en) | 2012-12-06 | 2012-12-06 | Preparation containing lurasidone hydrochloride and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103006661A true CN103006661A (en) | 2013-04-03 |
| CN103006661B CN103006661B (en) | 2015-02-18 |
Family
ID=47956127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210519854.1A Active CN103006661B (en) | 2012-12-06 | 2012-12-06 | Preparation containing lurasidone hydrochloride and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103006661B (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104606133A (en) * | 2015-01-07 | 2015-05-13 | 万特制药(海南)有限公司 | Oral lurasidone suspension and preparation method thereof |
| CN104971046A (en) * | 2014-04-08 | 2015-10-14 | 成都康弘药业集团股份有限公司 | Quick-release granules containing lurasidone hydrochloride and quick-release preparation of quick-release granules |
| WO2016012898A1 (en) * | 2014-07-25 | 2016-01-28 | Lupin Limited | Oral pharmaceutical composition of lurasidone |
| CN106377514A (en) * | 2016-09-24 | 2017-02-08 | 万全万特制药江苏有限公司 | Lurasidone hydrochloride dispersible tablet |
| CN107007565A (en) * | 2017-03-17 | 2017-08-04 | 万全万特制药江苏有限公司 | A kind of Lurasidone HCl oral disintegrating tablet and preparation method thereof |
| CN110833532A (en) * | 2019-12-19 | 2020-02-25 | 赵洁 | Rapidly-released lurasidone hydrochloride tablet and preparation process thereof |
| US11090272B2 (en) | 2017-01-06 | 2021-08-17 | Sunshine Lake Pharma Co., Ltd. | Lurasidone solid dispersion and preparation method thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109498587A (en) * | 2017-09-15 | 2019-03-22 | 北京万全德众医药生物技术有限公司 | The preparation method of Lurasidone HCl piece |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101184489A (en) * | 2005-05-26 | 2008-05-21 | 大日本住友制药株式会社 | Pharmaceutical composition |
| CN102688209A (en) * | 2012-06-21 | 2012-09-26 | 李兴惠 | Lurasidone tablet and preparation method thereof |
-
2012
- 2012-12-06 CN CN201210519854.1A patent/CN103006661B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101184489A (en) * | 2005-05-26 | 2008-05-21 | 大日本住友制药株式会社 | Pharmaceutical composition |
| CN102688209A (en) * | 2012-06-21 | 2012-09-26 | 李兴惠 | Lurasidone tablet and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 雷同康: "分散片的处方和工艺", 《中国医药工业杂志》 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104971046A (en) * | 2014-04-08 | 2015-10-14 | 成都康弘药业集团股份有限公司 | Quick-release granules containing lurasidone hydrochloride and quick-release preparation of quick-release granules |
| CN104971046B (en) * | 2014-04-08 | 2018-01-09 | 成都康弘药业集团股份有限公司 | A kind of immediate-release granules and its quick releasing formulation containing Lurasidone HCl |
| WO2016012898A1 (en) * | 2014-07-25 | 2016-01-28 | Lupin Limited | Oral pharmaceutical composition of lurasidone |
| CN104606133A (en) * | 2015-01-07 | 2015-05-13 | 万特制药(海南)有限公司 | Oral lurasidone suspension and preparation method thereof |
| CN106377514A (en) * | 2016-09-24 | 2017-02-08 | 万全万特制药江苏有限公司 | Lurasidone hydrochloride dispersible tablet |
| US11090272B2 (en) | 2017-01-06 | 2021-08-17 | Sunshine Lake Pharma Co., Ltd. | Lurasidone solid dispersion and preparation method thereof |
| CN107007565A (en) * | 2017-03-17 | 2017-08-04 | 万全万特制药江苏有限公司 | A kind of Lurasidone HCl oral disintegrating tablet and preparation method thereof |
| CN110833532A (en) * | 2019-12-19 | 2020-02-25 | 赵洁 | Rapidly-released lurasidone hydrochloride tablet and preparation process thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103006661B (en) | 2015-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103006661B (en) | Preparation containing lurasidone hydrochloride and preparation method thereof | |
| CN101184489B (en) | Pharmaceutical composition | |
| ES2399810T3 (en) | Solid pharmaceutical dosage form comprising a solid dispersion of ritonavir and lopinavir | |
| Shihora et al. | Superdisintegrants, utility in dosage forms: a quick review | |
| JP2021178871A (en) | Formulations of enzalutamide | |
| ES2675548T3 (en) | Solid pharmaceutical form containing lopinavir | |
| JP2005517690A (en) | Immediate release dosage form containing solid drug dispersion | |
| BRPI0809282A2 (en) | '' GRANULAR MATERIAL, DETERMINATION FOR A DOSAGE FORM, DOSAGE FORM, DIRECT COMPRESSION PROCESS FOR PREPARING A DOSAGE FORM, USE OF GRANULAR MATERIAL AND PROCESS FOR GRANULATING A POLYMER POWDER '' | |
| US8367080B2 (en) | Pharmaceutical formulation for use in HIV therapy | |
| JP2007308480A (en) | Solid preparation containing enteric solid dispersion | |
| CN104337790B (en) | Lurasidone hydrochloride oral preparation and preparing method of lurasidone hydrochloride oral preparation | |
| JP2007308479A (en) | Solid-dispersed substance preparation | |
| CN103356616A (en) | Bilastine-containing pharmaceutical composition and preparation method thereof | |
| CN102688210A (en) | Lurasidone medicine composition and preparation method | |
| TWI724534B (en) | Cellulose powder, lozenges and methods for manufacturing lozenges | |
| CN100379406C (en) | Method for preparing tiny pellets of difficult soluble drugs and formulation containing the pellets | |
| JP5576922B2 (en) | Solid formulation comprising an enteric solid dispersion | |
| CN102755300A (en) | Voriconazole composition and preparation method thereof | |
| CN101884791B (en) | Latrozole co-ground material, preparation method thereof and medicament composition having same | |
| CN104382859B (en) | A kind of SLGT2 inhibitor particle and preparation method thereof | |
| CN102688209A (en) | Lurasidone tablet and preparation method thereof | |
| CN110833532A (en) | Rapidly-released lurasidone hydrochloride tablet and preparation process thereof | |
| CN106913538A (en) | A kind of Abiraterone acetate sublingual tablets and preparation method thereof | |
| CN111053753A (en) | Rivaroxaban pharmaceutical composition and preparation method thereof | |
| CN105726499B (en) | Rivaroxaban pharmaceutical composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160122 Address after: No. 9 Qixia Xianlin Avenue District of Nanjing City, Jiangsu province 210049 Patentee after: NANJING HAILING PHARMACEUTICAL CO., LTD. OF YANGTZE RIVER PHARMACEUTICAL Group Address before: 210042 Xuanwu District, Xuanwu District, Jiangsu, Nanjing No. 699 -18 Patentee before: JIANGSU SIMCERE PHARMACEUTICAL Co.,Ltd. Effective date of registration: 20160122 Address after: 210042 Xuanwu District, Xuanwu District, Jiangsu, Nanjing No. 699 -18 Patentee after: JIANGSU SIMCERE PHARMACEUTICAL Co.,Ltd. Address before: 210042 Xuanwu District, Xuanwu District, Jiangsu, Nanjing No. 699 -18 Patentee before: JIANGSU SIMCERE PHARMACEUTICAL R & D Co.,Ltd. Patentee before: JIANGSU SIMCERE PHARMACEUTICAL Co.,Ltd. |